

CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-04 Medicare Claims Processing	Centers for Medicare & Medicaid Services (CMS)
Transmittal 4048	Date: May 11, 2018
	Change Request 10624

Transmittal 4025, dated April 20, 2018, is being rescinded and replaced by Transmittal 4048, dated, May 11, 2018 to update the policy section for HCPCS code Q9995. All other information remains the same.

SUBJECT: Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes - July 2018 Update

I. SUMMARY OF CHANGES: The HCPCS code set is updated on a quarterly basis. This instruction informs the contractors of updating specific drug/biological HCPCS codes.

Beginning on July 1, 2018, the following HCPCS codes will be established.

Q9991 Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg

Q9992 Injection, buprenorphine extended-release (sublocade), greater than 100 mg

Q9993 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg

Q9995 Injection, emicizumab-kxwh, 0.5 mg

This Recurring Update Notification (RUN) applies to Chapter 17, Section 10 of the Claims Processing Manual.

EFFECTIVE DATE: July 1, 2018

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: July 2, 2018

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-Only One Per Row.

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE
N/A	N/A

III. FUNDING:

For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is

not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

IV. ATTACHMENTS:

Recurring Update Notification

Attachment - Recurring Update Notification

Pub. 100-04	Transmittal: 4048	Date: May 11, 2018	Change Request: 10624
-------------	-------------------	--------------------	-----------------------

Transmittal 4025, dated April 20, 2018, is being rescinded and replaced by Transmittal 4048, dated, May 11, 2018 to update the policy section for HCPCS code Q9995. All other information remains the same.

SUBJECT: Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes - July 2018 Update

EFFECTIVE DATE: July 1, 2018

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: July 2, 2018

I. GENERAL INFORMATION

A. Background: The HCPCS code set is updated on a quarterly basis. The July 2018 HCPCS file includes 4 new HCPCS codes: Q9991, Q9992, Q9993 and Q9995.

B. Policy: Effective for claims with dates of service on or after July 1, 2018, HCPCS codes Q9991, Q9992, Q9993, and Q9995 will be payable for Medicare. Part B payment for HCPCS code Q9995, Injection, emicizumab-kx, 0.5mg, will include the clotting factor furnishing fee.

HCPCS Code: Q9991

Short Description: Buprenorph xr 100 mg or less

Long Description: Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg

TOS Code: 1

Medicare Physician Fee Schedule Database (MPFSDB) Status Indicator: E

HCPCS Code: Q9992

Short Description: Buprenorphine xr over 100 mg

Long Description: Injection, buprenorphine extended-release (sublocade), greater than 100 mg

TOS Code: 1

MPFSDB Status Indicator: E

HCPCS Code: Q9993

Short Description: Inj., triamcinolone ext rel

Long Description: Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg

TOS Code: 1,P

MPFSDB Status Indicator: E

 HCPCS Code: Q9995

Short Description: Inj. emicizumab-kxwh, 0.5 mg

Long Description: Injection, emicizumab-kxwh, 0.5 mg

TOS Code: 1

MPFSDB Status Indicator: E

II. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Responsibility										
		A/B MAC			D M E M A C S	Shared- System Maintainers				Other		
		A	B	H H H		F I S S	M C S	V M S	C W F			
10624.1	Contractors shall make user changes to accept Q9991, Q9992, Q9993 and Q9995 as valid HCPCS codes for dates of service on or after July 1, 2018.	X	X	X	X					X	BCRC, IOCE	
10624.2	Contractors shall use Type of Service (TOS) 1 for Q9991, Q9992 and Q9995, and TOS 1,P for Q9993 for dates of service on or after July 1, 2018.	X	X		X					X		
10624.3	The Common Working File (CWF) shall use categories 60 and 17 for Q9991, Q9992, Q9993 and Q9995 for dates of service on or after July 1, 2018.									X	IOCE	
10624.4	The contractor shall use the first 100 characters of the long descriptions of HCPCS codes Q9991, Q9992, Q9993 and Q9995 below to update the Medicare Summary Notice (MSN) descriptors, effective when the MSN is processed on or after 7/1/2018: Q9991 Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg Q9992 Injection, buprenorphine extended-release (sublocade), greater than 100 mg								X			

Number	Requirement	Responsibility								
		A/B MAC			D M E M A C	Shared-System Maintainers				Other
		A	B	H H H		F I S S	M C S	V M S	C W F	
	Q9993 Injection, triamcinolone acetoneide, preservative-free, extended-release, microsphere formulation, 1 mg Q9995 Injection, emicizumab-kxwh, 0.5 mg									

III. PROVIDER EDUCATION TABLE

Number	Requirement	Responsibility				
		A/B MAC			D M E M A C	C E D I
		A	B	H H H		
10624.5	MLN Article: A provider education article related to this instruction will be available at http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/ shortly after the CR is released. You will receive notification of the article release via the established "MLN Matters" listserv. Contractors shall post this article, or a direct link to this article, on their Web sites and include information about it in a listserv message within 5 business days after receipt of the notification from CMS announcing the availability of the article. In addition, the provider education article shall be included in the contractor's next regularly scheduled bulletin. Contractors are free to supplement MLN Matters articles with localized information that would benefit their provider community in billing and administering the Medicare program correctly.	X	X	X	X	

IV. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements: N/A

"Should" denotes a recommendation.

X-Ref Requirement Number	Recommendations or other supporting information:

Section B: All other recommendations and supporting information: N/A

V. CONTACTS

Pre-Implementation Contact(s): Felicia Eggleston, 410-786-9287 or felicia.eggleston@cms.hhs.gov ,
Prabath Malluwa-wadu, 410-786-4620 or prabath.malluwa-wadu@cms.hhs.gov

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VI. FUNDING

Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 0